Botensilimab
- Generic Name
- Botensilimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2408310-37-0
- Unique Ingredient Identifier
- 1Z5YC3ME5N
- Background
Botensilimab is under investigation in clinical trial NCT03860272 (Fc-engineered Anti-ctla-4 Monoclonal Antibody in Advanced Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
- Conditions
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 112
- Registration Number
- NCT05845450
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Lombardia/MI, Italy
Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2023-01-05
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 63
- Registration Number
- NCT05672316
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC
- Conditions
- Interventions
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Bruno Bockorny
- Target Recruit Count
- 24
- Registration Number
- NCT05632328
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 78
- Registration Number
- NCT05630183
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸USC Norris Oncology, Newport Beach, California, United States
🇺🇸Illinois Cancer Specialists, Arlington Heights, Illinois, United States
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 234
- Registration Number
- NCT05608044
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸Memorial Sloan Kettering, New York, New York, United States
🇷🇺Branch office of " Hadassah Medical Ltd", Moscow, Russian Federation
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
- Conditions
- Interventions
- First Posted Date
- 2022-09-07
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT05529316
- Locations
- 🇧🇪
Universitair Ziekenhuis Brussel, Jette, Belgium
🇪🇸Hospital Clinic Barcelona, Barcelona, Spain
🇪🇸Consorcio Hospital General Universitario de Valencia, Valencia, Spain
Study of AGEN1571 in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT05377528
- Locations
- 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT04121676
- Locations
- 🇺🇸
Mary Crowley Cancer Research Center, Dallas, Texas, United States
🇺🇸Roswell Park Comprehensive Cancer Care, Buffalo, New York, United States
🇺🇸Columbia University, New York, New York, United States
Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
- Conditions
- Interventions
- First Posted Date
- 2019-07-22
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 28
- Registration Number
- NCT04028063
- Locations
- 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
- First Posted Date
- 2019-03-01
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 550
- Registration Number
- NCT03860272
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Providence Portland Cancer Center, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.